GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - DISC MEDICINE INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, or cash flow) provided for fiscal years or quarters.
• Capitalization: Company confirmed ~$1.1 billion in pro forma capital (cash on books + recent financing) sufficient to fund the Porphyria launch and advance two Phase 2 assets to Phase 3.
• Workforce: Headcount at 170; plans to add a commercial team (targeting ~24 reps for launch) and additional resources for Phase 3 trials.

Business-Segment Outlook:

• Porphyria (BIT-200/BIT-201): Launch targeted for 12–16 months from now; targeting an initial "engaged" market of ~6,000 patients, with a longer-term ramp to reach 8,000 "disengaged" patients.
• Myeloproiferative Neoplasms (MF): Goal is to align with FDA on a pivotal Phase 3 trial design by the upcoming ASH meeting to access the full ~22,000 US anemic myelofibrosis patient pool; trial initiation expected "next year" (2025).
• Polycythemia Vera (PV): Pivotal trial initiation expected "next year" (2025); aiming for a Phase 2 readout showing 70–80% phlebotomy-free efficacy at the next ASH meeting.
• Inflammatory Bowel Disease (IBD): Pilot trial already initiated to evaluate selcodabarant; signal-seeking studies also planned for sickle cell disease.
• Pipeline Progression: Three core programs (Porphyria, MF, PV) all projected to reach Phase 3 or commercialization within the next 12 months.

Market and Competitive Outlook:

• Porphyria: Launch model based on historical rare disease curves (e.g., HAE, PNH); pricing expected to align with established rare disease graphs ($300k–$600k/year range, comparable to hepatic porphyria products); initial focus on 100 top sites (1,600 patients) followed by broader coverage.
• MF-Anemia: No approved therapies currently exist for anemia in this population; physician bar for prescription set at 30% response rate, with company data showing 50% response (clinically significant).
• PV: Market size of 50,000–100,000 US patients; competitive landscape includes Resveratide and 3 other agents in late-stage; company differentiates via self-administered auto-injector, minimal side effects, and monthly dosing capability to allow rapid dose titration/reversal of anemia.
• Competitive Positioning: Views itself as having "no competition" in MF anemia; in PV, positioning as the "drug of choice" based on safety and tolerability rather than just efficacy (all competitors targeting 70–80% phlebotomy-free rate).

Macro / Industry Outlook:

• Ex-U.S. Expansion: Plans to enter European markets due to proportional patient density; acknowledges Market Fairness (MFN) legislation may lower European price points but anticipates ability to bridge the gap via a lean, efficient commercial model.
• Pricing Strategy: Willing to utilize extended half-life antibodies for larger disease segments (e.g., IBD, MPN) to enable different price points and potentially non-chronic dosing structures.

Strategic Initiatives:

• Commercial Launch: Building a 24-person sales force to target the initial 6,000 engaged Porphyria patients; implementing a call-center approach for the 8,000 disengaged patient cohort.
• Asset Diversification: Developing a portfolio strategy that may include chronic dosing (for severe MPN) vs. single-dose or extended half-life approaches (for less severe IBD/sickle cell) to optimize pricing and convenience.
• Operational Scale: Transitioning from a lean, research-focused organization to a commercial entity with expanded Phase 3 trial capabilities.

Risks and Headwinds to Outlook:

• Regulatory: FDA alignment on Phase 3 endpoints and trial design for MF is pending; PV Phase 2/3 transition relies on assumed precedent from Minrella's approval without a formal end-of-Phase 2 meeting completed.
• Clinical: PV product must still prove "essentially no injection site reactions" and "no anemia" to achieve the optimal safety profile; Phase 3 success hinges on hitting the 70–80% phlebotomy-free target.
• Operational/Commercial: Potential challenge in activating the 8,000 "disengaged" Porphyria patients who previously retreated from care; MFN legislation impacting European revenue realization.
• Competition: Rapid convergence of competitors in the PV space (including long-acting agents) could compress differentiation value if efficacy targets are met by all.

Management Tone on the Future:

• High Confidence: Describes Phase 3 Porphyria readout as "phenomenal" and "life-altering"; expresses excitement about the "uniquely clear" opportunity in MF anemia due to lack of competition.
• Strategic Clarity: Demonstrates a clear roadmap for the next 12–16 months, viewing the company as transitioning from a clinical-stage biotech to a commercial entity with multiple late-stage assets.
• Optimistic but Grounded: While confident in data (citing 70–80% response rates and normalization of hemoglobin), acknowledges the need to prove safety and tolerability in PV and secure FDA agreement on MF trial design.

Miscellaneous:

• ASH Presentation: Confirmed presentation of Phase 2 data (60+ patients) for MF and Q4-week dosing data for PV at the upcoming ASH meeting.
• Patient Segmentation: Detailed breakdown of Porphyria market into 1,600 (top sites), 4,000 (larger group), and 8,000 (disengaged) to guide sales ramp strategy.